Generali Asset Management SPA SGR Has $10.41 Million Stock Holdings in Intuitive Surgical, Inc. $ISRG

Key Points

• Generali Asset Management reduced its stake in Intuitive Surgical by 9.5%, leaving it with approximately $10.41 million worth of shares as of its latest SEC filing.
• Insider transactions included a director selling 335 shares for over $147,000, indicating significant decreases in ownership among officials as they sold a total of 45,224 shares valued at $21.7 million last quarter.
• The stock currently shows a market capitalization of $156.44 billion and an average price target of $585.71 from various analysts, who maintain a consensus rating of "Moderate Buy."

Generali Asset Management SPA SGR trimmed its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 9.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,151 shares of the medical equipment provider's stock after selling 2,009 shares during the period. Generali Asset Management SPA SGR's holdings in Intuitive Surgical were worth $10,407,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Chilton Capital Management LLC increased its position in shares of Intuitive Surgical by 614.3% in the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 43 shares in the last quarter. Elite Financial Inc. acquired a new position in Intuitive Surgical in the 1st quarter worth approximately $26,000. LFA Lugano Financial Advisors SA purchased a new position in Intuitive Surgical during the 1st quarter worth approximately $30,000. TD Capital Management LLC raised its stake in Intuitive Surgical by 300.0% during the 1st quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 45 shares during the period. Finally, 1248 Management LLC purchased a new stake in shares of Intuitive Surgical in the first quarter valued at $30,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, Director Amy L. Ladd sold 335 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $440.69, for a total transaction of $147,631.15. Following the transaction, the director owned 739 shares in the company, valued at $325,669.91. This trade represents a 31.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Myriam Curet sold 4,500 shares of the business's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the sale, the executive vice president owned 353 shares of the company's stock, valued at $173,845.44. The trade was a 92.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 45,224 shares of company stock worth $21,716,492. 0.70% of the stock is owned by corporate insiders.

Intuitive Surgical Stock Up 0.2%

ISRG stock opened at $436.39 on Wednesday. The company has a market capitalization of $156.44 billion, a price-to-earnings ratio of 60.86, a P/E/G ratio of 4.58 and a beta of 1.61. The firm has a 50 day moving average of $456.92 and a two-hundred day moving average of $497.02. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.93 by $0.26. The business had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. Intuitive Surgical's quarterly revenue was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.78 EPS. On average, research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ISRG. Piper Sandler reiterated an "overweight" rating and set a $595.00 price target (up previously from $575.00) on shares of Intuitive Surgical in a report on Wednesday, July 23rd. The Goldman Sachs Group decreased their price objective on Intuitive Surgical from $621.00 to $567.00 and set a "buy" rating for the company in a research report on Wednesday, October 1st. Wells Fargo & Company lifted their target price on Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a research note on Wednesday, July 23rd. Truist Financial increased their price target on shares of Intuitive Surgical from $590.00 to $600.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Finally, Erste Group Bank restated a "hold" rating on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Fourteen equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $585.71.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.